Outsourced Pharma: ADC Capacity Update
Published on November 18, 2024
We are a leading CRO and CDMO that specializes in the development and manufacture of complex biologics, bioconjugates, and antibody-drug conjugates (ADCs).
Recently Petra Dieterich Ph.D, Senior Vice President at Abzena spoke to Outsourced Pharma about our ADC services and solutions, as well as capacity updates.
About Abzena
By seamlessly integrating early R&D with comprehensive cGMP manufacturing capabilities in biologics, chemistry, and conjugation, Abzena consistently delivers high-quality products and data packages that support our partners’ regulatory submissions and product requirements.
The post Outsourced Pharma: ADC Capacity Update appeared first on Abzena.